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Abstract
Neuregulin 1 (NRG1) has been implicated in several disorders including breast cancer, multiple
sclerosis, and schizophrenia. Also, recent evidence suggests that NRG1 may play a role in
regulation of inflammation and immune system response. We therefore hypothesized that a
schizophrenia-associated missense mutation (valine to leucine) we identified within the
transmembrane region of NRG1 would also be linked to immune dysregulation. We used plasma
samples from families carrying the mutation to measure levels of antibodies to 41 autoimmune
markers and six cytokines (IL-1b, IL-6, IL-10, IL-8, IL-12p70, and TNF-α) and used these levels
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as quantitative traits to evaluate association with the NRG1 mutation, using FBAT. Next, we used
Epstein–Barr virus-transformed B cells from heterozygous mutation carriers and wild-type
individuals to evaluate protein and mRNA cytokine expression in vitro using quantitative PCR and
ELISA assays. In vivo, increased levels of 25 autoimmune markers as well as elevated levels of
cytokines were significantly associated with the NRG1 mutation. In vitro, we observed a
significant increase in protein secretion levels of IL-6, TNF-α, and IL-8 in mutation carriers
compared with controls. At the mRNA level, we observed a significant increase in IL-6
expression, while IL-4 levels appeared to be downregulated in heterozygous individuals compared
with wild-type controls. This is the first report of association of a NRG1 mutation with immune
dysregulation. This study could contribute towards understanding the role of NRG1 in the
pathogenesis of schizophrenia and other disorders in which inflammation plays an important role.
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Introduction
Neuregulin 1 (NRG1) mediates cell–cell interactions via activation of ErbB receptors, and is
known to be involved in several biological processes, including cell proliferation, migration,
and apoptosis, affecting multiple systems [1]. In the brain, NRG1 plays roles in processes
such as neuronal migration, gliogenesis, neurotransmitter expression, and myelination,
which are thought to account for its involvement in brain disorders such as multiple sclerosis
and schizophrenia. More recently, several lines of evidence have emerged, suggesting that
NRG1 may also be implicated in regulation of the immune response [2,4] possibly by
functioning as an anti-inflammatory or antioxidant agent. Studies in rodents have shown that
NRG1 has a neuroprotective role during conditions of ischemia or trauma [3]. It has been
reported that human genetic variation in NRG1 modulates the effects of stress on early
atherosclerosis [4], a well-established inflammatory process. Also, NRG1 has been shown to
influence cell adhesion of immune cells [5] and to attenuate the release of free radicals from
microglial cells [2]. More recently, it was shown that in immunedeficient mice, the levels of
a splice variant of NRG1 were decreased in medial prefrontal cortices, signifying a crosstalk
between NRG1 and the immune system [6].
Immune system abnormalities have been observed in patients with psychiatric disorders
such as schizophrenia [7,8], as evidenced by increased expression of proinflammatory
cytokines and high levels of autoantibodies. Incidence of suffering from an autoimmune
disease is correlated with a 45% increase in risk for schizophrenia [9]. The mechanism by
which the immune system may contribute to development of psychiatric disorders is not
well understood.
We previously identified a novel NRG1 mutation associated with schizophrenia in the
founder population of the Central Valley of Costa Rica (CVCR). This mutation causes the
change of a residue (valine to leucine, G>T) in the transmembrane domain of the NRG1
protein [10]. The transmembrane domain is thought to be important for cleavage of NRG1
via metalloproteases and secretases. Recently, it was shown that the V>L mutation affects
gamma-secretase cleavage of the intracellular domain of NRG1 [11], which has been shown
to act as a transcription modulator [12]. This suggests the relevance of the V>L mutation in
NRG1 protein function.
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Given the involvement of NRG1 in immune system response and the apparent importance of
the V>L mutation in NRG1 cleavage, we hypothesized that this mutation could contribute to
immune system dysregulation, thereby possibly playing a role in development of immune-
related disorders, such as schizophrenia.
Materials and methods
Ethics statement
Peripheral leucocytes, DNA, and plasma were isolated from blood of subjects from the
CVCR, at the time of recruitment, as previously described [10], in accordance with the
principles of the Declaration of Helsinki with approval from the Institutional Review Boards
of the University of Costa Rica and the University of Texas Health Science Center at San
Antonio.
Plasma isolation and generation of lymphoblastoid cell lines
For plasma isolation, blood was spun within 30 min of collection at 3,000×g for 3 min.
Plasma was aspirated by pipette and frozen in 0.5-mL aliquots at −80°C until tested. Plasma
was obtained from 45 individuals, from 14 separate families (Fig. 1), for measurement of
autoantibodies and cytokine levels, to be used for quantitative trait analyses, as described
below.
Lymphoblastoid cell lines (LCLs) were generated from leucocytes using LeucoPREP brand
cell separation tubes (Becton Dickinson Labware) and transformed using Epstein–Barr virus
(EBV). For all experiments, cells were grown in RPMI 1640 medium with 2 mM L-
glutamine and 15% bovine growth serum at 37°C in a humidified 5% CO2 chamber to a
density of approximately 2×106 cells/ml.
Cell lines of unaffected unrelated individuals were selected for the experiments described
below. All individuals had one first degree relative with psychosis. The cell lines used were
from wild type (Val/Val, N=6; three males, three females, average age at blood draw
40±20.8 year) and heterozygous T allele carriers (Val/Leu, N=5; two males, three females,
average age at blood draw 44±17 year).
All experiments described below were repeated at least twice. While conducting the
experiments, the investigators were blinded to the experimental groups.
Autoimmune biomarker analysis
A commercial multiplex assay that concurrently estimates the levels of antibodies to 43
autoimmune biomarkers (Table 1) was used (Rules-Based Medicine Inc., Austin, TX, USA).
This multiplex microbead assay measures proteins in a similar manner to standard sandwich
ELISA, with comparable sensitivity and range [13]. Fifty microliters of plasma was used for
analysis.
Fluorescence-activated cell sorting
For cytokine quantitation, a validated cytometric bead array system (BD Biosciences) [14]
was used to simultaneously measure levels of six different human cytokines from plasma
samples and LCL supernatants using fluorescently conjugated detection antibodies. The
minimum limits of detection (pg/ml) are 3.6, 7.2, 2.5, 3.3, 3.7, and 1.9 for IL-8, IL-1b, IL-6,
IL-10, TNF-α, and IL-12p70, respectively. Data were analyzed on a FACSCalibur flow
cytometer using the BD CBA software. For IL-6, fluorescence-activated cell sorting (FACS)
data were validated using the Human IL-6 ELISA Kit II (BD Biosciences).
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RNA isolation and gene expression studies
RNA isolation from LCLs was carried out using the Trizol method (Invitrogen), and
samples were cleaned up using the Qiagen RNeasy plus Kit. Quantitative PCR was carried
out using the RT2 Profiler PCR Array system (SABiosciences), using a 7900HT Standard
Real Time PCR system (Applied Biosystems). For the pathway-based approach, we used the
“Common Cytokine” array (PAHS-021, SABiosciences). Each array tests 83 different genes
of interest (GOI) and five endogenous housekeeping genes (HKG) in a 96-well format.
Significant array data were validated using PCR assays (SABiosciences) specific for
individual cytokine genes (IL-6, IL-4), with beta-2-microglobulin (B2M) used as the
endogenous HKG. Expression data were analyzed using the ΔΔCt method.
Statistical analysis
The autoantibody and cytokine plasma levels were used as quantitative traits to test for
association with the NRG1 mutation in 14 informative CVCR families using FBAT. The
program computes bi-allelic tests of association with quantitative traits, using the following
commands: trait (Biomarker); offset 0.000; model additive; test bi-allelic; minsize 10;
min_freq 0.000; P 1.000. Quantitative FBAT builds on the traditional transmission
disequilibrium test, which compares the transmission of marker alleles from parents with
affected offspring. With quantitative traits (i.e., levels of cytokines in plasma), the allelic
transmissions among offspring who have high quantitative trait values are compared with
transmission among offspring with low trait values [15,16]. In other words, the quantitative
trait takes the place of affected status as the phenotype of interest.
For in vitro analyses, two-tailed, unpaired Student t tests were used as appropriate. All
results are expressed as mean±SD.
Results
Autoantibody and cytokine measurements in plasma from Costa Rican families
We first measured levels of 41 different autoantibodies (Table 1) in plasma from 14 CVCR
families, informative for the V>L mutation. These families were recruited and genotyped for
the NRG1 mutation as previously described [10]. Of the 14 families, seven were part of the
original study [10], and seven were new additional families, recruited at a later date. These
14 families were chosen, out of 206 available CVCR families, because they carried the
NRG1 mutation and the transmission of the rare T allele from parent to offspring could be
inferred, and we had plasma samples available for all genotyped family members.
The families were comprised of 45 individuals; 14 homozygous normal, 29 heterozygous,
and two homozygous rare (Fig. 1). Of the 45 individuals, 14 were affected and 31 were
unaffected (Fig. 1). The DSM-IV diagnoses for affected individuals in these families were as
follows: schizophrenia (nine), bipolar disorder type I with psychosis (one), schizoaffective
disorder depressed type (one), major depressive episode with psychosis (one), and psychotic
disorder not otherwise specified (two). The T allele was not found to be significantly
associated with schizophrenia or psychosis in these 14 families by FBAT.
Levels of antibodies were measured in plasma from the 45 individuals by using a validated
multiplex immunoassay developed by Rules-Based Medicine
(www.rulesbasedmedicine.com). The mean values of antibody levels for wild type and
mutants are listed in supplemental Table 1. For quantitative analysis, antibody levels were
normalized using natural log. We used the normalized levels as quantitative traits to perform
a quantitative family based association test (qFBAT) to evaluate association of the NRG1
mutation with antibody levels. Quantitative FBAT utilizes the levels of biomarkers as the
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phenotype of interest, and therefore, analysis is done without regard to affected status. This
is of importance because the goal of this study is to determine the association of the NRG1
mutation with immune dysregulation, independent of psychiatric diagnosis. Higher than
expected levels of antibodies to 25 different autoimmune markers were significantly
associated with the NRG1 mutation (T allele; Z value >2, P<0.05) in the 14 families (Table
1). Although the individual P values are not corrected for multiple testing, the fact that
greater than half of the markers, 25 out of 41, showed positive association with the mutation
suggested a “signature” of abnormal immune regulation in these families, leading to a
generalized immune activation as manifested by increased development of antibodies
against endogenous antigens. There is a possibility that the observed increased antibody
levels could be due to high schizophrenia loading in these families. However, an inspection
of the family pedigrees reveals that there is an equal loading of psychiatric diagnosis on G G
and G T individuals in these families (Fig. 1).
Next, we surmised that if indeed there was a generalized immune dysregulation in carriers of
the V>L mutation, levels of circulating immune mediators (cytokines) should also be
elevated in the 14 families. We measured levels of six different cytokines (IL-1b, IL-6,
IL-10, IL-8, IL-12p70, and TNF-α) in plasma from the 45 individuals, using a cytometric
bead array system followed by FACS analysis. The mean cytokine levels for each genotype
group are listed in supplemental Table 1. Statistical analysis using qFBAT indicated that
higher than expected levels of IL-1b, IL-6, IL-10, IL-12p70, and TNF-α were significantly
associated (Z value >2, P<0.05) with the NRG1 mutation in these 14 families (Table 1).
Immunological profiling of lymphoblastoid cell lines
Considering that multiple confounding factors could affect measurements of antibody titers
and cytokines in vivo, we sought to obtain more direct evidence for an effect of NRG1 in
vitro by comparing the immunological features of EBV-transformed B cells derived from
heterozygous vs. wild-type individuals. The study of LCLs is uniquely suited to the
investigation of genetic polymorphisms in immune activation. In vitro, the EB virus infects
resting (naive or memory) B lymphocytes and transforms them into immortalized,
polyclonal LCLs. Regardless of their origin, most EB virus genome-carrying cell lines are
thought to contain B cells that are “frozen” at the lymphoblast stage of differentiation [17].
In other words, the analysis of the immune phenotype of LCLs can provide information
about the overall immune activation of the donor at the time of sample collection.
Furthermore, LCLs are ideal for the study of the effects of polymorphisms in the
transcriptome. Concurrent genome-wide SNP and expression studies revealed that genes
expressed in LCLs are enriched in gene ontology categories of immune response, and there
is a significant heritability for these traits, emphasizing the value of the use of LCLs for the
study of genetic variation in immunity [18]. In addition, data mining mRNA expression
arrays of LCLs from 15 CEPH/Utah families revealed expression of NRG1 [18], suggesting
that LCLs could be informative about the effects of the NRG1 V>L mutation in immune
dysregulation. [Gene Expression Omnibus database, DataSet GDS1048,
(http://www.ncbi.nlm.nih.gov/geo.)].
Measurement of cytokine expression levels in LCLs
We first measured expression of IL-8, IL-1b, IL-6, IL-10, TNF-α, and IL-12p70 in
supernatants from LCLs of wild-type (Val/Val, N=6) and heterozygous T allele carriers
(Val/ Leu, N=5). The cell lines were chosen from unrelated, unaffected individuals, each
with a first degree relative with psychosis. Because the family loading for psychosis is equal
for all samples and the individuals themselves do not suffer from any psychiatric disorder,
we can directly investigate the effect of the V>L mutation on cytokine expression, without
the confounding factor of an existing psychiatric disorder. The five T allele carriers were
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chosen from the 14 informative families described above, each from a different family. As
described, only two homozygous mutation carriers have been identified in the CVCR
population. Both of these individuals have a schizophrenia diagnosis. Given that the present
experimental design excluded affected individuals, for all experiments described below,
only heterozygous carriers were used.
Equal numbers of cells were plated overnight, and cytokine levels were evaluated from
supernatants, 24 h after plating, using FACS. Cell counts were not found to be different
between wild type and mutants 24 h after plating (data not shown). We found that, compared
with LCLs from wild-type carriers, LCLs from T allele carriers produced significantly
higher levels of proinflammatory cytokines (Fig. 2a). TNF-α, IL-6, and IL-8 showed
significantly higher levels in the mutants compared with controls (two-tailed Student t,
P=0.0187, 0.0166, 0.0323, respectively).
We validated the IL-6 results using an IL-6-specific ELISA. IL-6 supernatant levels,
normalized to total protein content, were observed to be significantly higher in mutants
compared with controls, confirming the results obtained in the six-cytokine kit (two-tailed
Student t, P=0.008) (Fig. 2b).
Next, a cytokine gene array (SABiosciences) was used to evaluate 83 cytokine mRNA levels
by quantitative PCR in the same cell lines as above, wild-type (N=6) and T allele carriers
(N=5). Four genes, IL-4, IL-6, IFNA2, and BMP8B, showed a significant difference between
the mutants and controls (Table 2).
The IL-4 and IL-6 results were validated using specific single gene assays. cDNA generated
from each individual cell line was assayed in duplicate using B2M as the endogenous
housekeeping control. We observed a 4.39-fold down-regulation of IL-4 and a 35.46-fold
up-regulation of IL-6 in mutants compared with controls (two-tailed Student t, P=0.014 and
0.0011 for IL4 and IL-6, respectively) (Table 3).
Discussion
Because of its multiple isoforms and various functional roles, NRG1 has been implicated in
the pathophysiology of a wide variety of disorders, including breast cancer [19]
schizophrenia and bipolar disorder [20] in human studies, and atherosclerosis [21],
myocardial dysfunction [22] and multiple sclerosis [23] in animal models. Interestingly,
immune system dysregulation has been implicated as a risk factor in all of these disorders.
Inflammation has been associated with poor prognosis in breast cancer [24].
Proinflammatory imbalance and uncontrolled immune response have been postulated as the
cause of acute myocardial infarction [25]. In schizophrenia, immune system abnormalities
such as increased expression of proinflammatory cytokines and high levels of autoantibodies
have been repeatedly reported [7,8]. Multiple sclerosis is characterized by immune system-
mediated demyelination and axonal loss. In an animal model of multiple sclerosis,
Marchionni et al. demonstrated that treatment with recombinant NRG1 caused greater
remyelination and decreased relapse rate, compared with untreated controls [23]. Increased
expressions of myelin basic protein and IL-10 were also observed. The modulation of
myelination by NRG1 in the CNS (but not in the PNS) is thought to be independent of
NRG1 ErbB signaling [26].
Our present results suggest the possibility that the NRG1 V>L mutation may be involved in
causing immune system dysregulation, which then, in combination with different specific
sets of genes and environmental factors, may lead to development of a particular disorder.
The NRG1 V>L mutation was first identified in a genetic study searching for schizophrenia-
causative mutations [10]. Although the NRG1 gene is one of the most promising
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schizophrenia candidate genes identified to date, no definite causative mutations within this
gene have been identified. Therefore, research aimed at determining the functional role of
NRG1 polymorphisms is an area of much interest. A deeper understanding of the biological
functionality of NRG1 variants could help to understand the role that NRG1 may play in
different pathological conditions.
In this study, we aimed to determine whether the V>L polymorphism could be associated
with immune system alterations. Given that this mutation occurs in the transmembrane
region of NRG1 and knocking out this region has been shown to cause schizophrenia-like
behavior in mice [27], we focused exclusively on this transmembrane mutation. However, it
is highly possible that other NRG1 variants, as well as SNPs within other schizophrenia
candidate genes (i.e., DISC1, dysbindin, and COMT), may also be associated with immune
system dysregulation. To our knowledge, SNPs in schizophrenia candidate genes other than
cytokines have not been previously reported to be associated with alterations in the immune
system. We hope our present results will encourage other researchers to investigate this
possibility.
We observed statistical evidence of increased plasma autoantibodies and proinflammatory
cytokines, including IL-6, TNF-α, and IL-1b in carriers of the V>L mutation.
Polymorphisms within IL-6 and IL-1b have been associated with schizophrenia [28,29].
Interestingly, it has been shown that polymorphisms in IL-1b and NRG1 genes interact
statistically with each other and are linked to schizophrenia [29]. Increased levels of
proinflammatory cytokines, in particular IL-6 and TNF-α, have been repeatedly observed in
schizophrenia patients [8]. IL-6 has also been implicated in worsening of autoimmune
disorders by causing blood–brain barrier disturbances and increased IgG secretion [8]. In a
large linkage study of Danish National Registers, a 45% greater risk of developing
schizophrenia in families with a history of autoimmune disorders was reported [9].
Furthermore, high levels of autoantibodies, including anticardiolipin, anti-histone, anti-
DNA, and anti-nuclear antibodies, have been reported in schizophrenic patients. Serum
antibodies against brainspecific regions such as the hippocampus, amygdala, and frontal
cortex have also been reported [8]. Na and Kim [30] reported reduced levels of IL-4, an anti-
inflammatory cytokine, in serum of schizophrenia patients compared with controls. This
correlates with our present data showing reduced IL-4 expression in cell lines of carriers of
the V>L mutation, compared with wild-type carriers (Fig. 2). Altogether, these studies
support the hypothesis that an overactive immune system could be an underlying causative
factor in schizophrenia development. Our current findings suggest that this over-activity
could be in part due to the NRG1 V>L mutation. Further studies with additional and larger
sets of samples from different populations need to be performed in order to corroborate
these results.
Investigation of the specific mechanism by which the V> L mutation leads to increased
immune activation is currently underway in our laboratory. One possibility is that the
change of V>L alters the proteolysis of NRG1 transmembrane proteins, resulting in different
availability of bioactive extracellular and intracellular domains of NRG1, which could
possibly lead to immune dysregulation. The NRG1 transmembrane domain interacts with
metalloproteinases, such as β and γ secretase, which form the bioactive extracellular and
intracellular domains of the proteins. The cleaved extracellular NRG1 domain interacts with
ErbB receptors and activates numerous downstream pathways, such as the AKT and ERK
pathways, which are involved in regulation of gene expression [31], and in leukocyte
activation and survival. In several different strains of mice that exhibit lupus-like
phenotypes, the level of phosphorylation of AKT and ERK in unstimulated B cells was
significantly elevated [32]. Moreover, the ERK pathway has been shown to regulate
cytokine expression [33].
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The intracellular NRG1 domain, formed via γ secretasemediated cleavage, migrates to the
nucleus and acts as a transcription factor, regulating mRNA expression of genes such as
BCL-XL, BAK, RIP, and OCT-3 [12]. Importantly, a recent study showed that the NRG1 V>L
mutation reduces γ-secretase cleavage in COS-1 cells [11], suggesting that this mutation
alters the function of the NRG1 protein. Differential availability of intracellular NRG1
associated with the V>L mutation may result in dysregulation of the mechanisms underlying
elimination of self-reactive B cells, which are mostly dependent on the counterbalancing
effects of pro-apoptotic proteins such BAK and anti-apoptotic proteins such as BCL-XL
[34]. Persistence of self-reactive B cells may lead to autoantibody production and in certain
cases full-blown autoimmune disorders [34].
Given that both the extracellular and intracellular NRG1 pathways are involved in regulation
of gene expression, it is possible that cytokine expression is regulated by either, or both, of
these pathways. Interestingly, IL-6 and IFN-γ have recently been shown to induce NRG1
cleavage in endothelial cells and enhance angiogenesis via NRG1 signaling in vitro [35].
Therefore, it is possible that the increase in IL-6 expression we have observed in the present
study may be a feedback mechanism compensating for reduced NRG1 cleavage due to the
V>L mutation. Further experiments need to be carried out to determine the exact mechanism
by which NRG1 may regulate cytokine expression.
Given the small sample sizes used in this study, our present results must be interpreted with
caution and should be replicated by independent samples. In addition, studies investigating
the potential association of other NRG1 polymorphisms with immune system dysregulation
are warranted.
In conclusion, our study is the first to report statistical association between a mutation in
NRG1 and immune system dysregulation. These findings could aid in the understanding of
the molecular mechanisms of inflammatory regulated disorders in which NRG1 plays an
important role.
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Fig. 1.
Pedigrees of informative families for the NRG1 G>T polymorphism. Subjects in black were
diagnosed as having a psychotic disorder (N=14), and subjects in white were diagnosed as
unaffected (N=31). Subjects not containing allele information were not genotyped.
Genotypes in parentheses were inferred. DSM-IV consensus diagnoses of the 14 affected
individuals were as follows: schizophrenia, nine; schizoaffective depressed, one; bipolar
disorder with psychosis, one; psychosis not otherwise specified, two; major depressive
episode with psychosis, one
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Fig. 2.
Expression of cytokines in lymphoblastoid cell lines. a Measurement of cytokine levels
using FACS in cell supernatants from LCLs of carriers of the NRG1 mutation compared
with controls. P=0.0187, 0.0166, and 0.0323, for TNF-α, IL-6, and IL-8, respectively (two-
tailed Student t). b Measurement of IL-6 levels using ELISA in cell supernatants from LCLs
of carriers of the NRG1 mutation and controls. P=0.008 (two-tailed Student t). Val/Leu, N=5
and Val/Val, N= 6. All concentration values are expressed in pg/ml. Data represent
logtransformed values. Asterisks represent significant P value
Marballi et al. Page 12
J Mol Med (Berl). Author manuscript; available in PMC 2011 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Marballi et al. Page 13
Ta
bl
e 
1
Q
ua
nt
ita
tiv
e 
FB
A
T 
an
al
ys
is
 o
f a
ut
oa
nt
ib
od
y 
an
d 
cy
to
ki
ne
 le
ve
ls
 in
 p
la
sm
a 
of
 1
4 
fa
m
ili
es
 in
fo
rm
at
iv
e 
fo
r t
he
 N
RG
1 
V
a 
l (
G
)>
Le
u 
(T
) m
ut
at
io
n
A
lle
le
S
E(
S)
V
ar
(S
)
Z
P
A
nt
ig
en
  A
nt
i-n
uc
le
ar
T
47
.6
00
36
.4
83
  2
1.
99
3
 2
.3
70
0.
01
77
  B
et
a-
2 
gl
yc
op
ro
te
in
T
35
8.
90
29
8.
81
48
29
.1
0.
86
5
0.
38
72
  C
om
pl
em
en
t f
ac
to
r 1
q
T
16
5.
70
13
9.
53
18
6.
13
1.
91
8
0.
05
51
  C
en
tro
m
er
e 
pr
ot
ei
n 
B
T
44
.8
00
34
.9
07
22
.3
10
2.
09
5
0.
03
62
  C
ol
la
ge
n 
ty
pe
 1
T
25
78
.6
18
47
.0
18
81
62
.1
6
1.
68
6
0.
09
17
  C
ol
la
ge
n 
ty
pe
 2
T
86
.5
00
68
.6
13
61
.7
27
2.
27
7
0.
02
28
  C
ol
la
ge
n 
ty
pe
 4
T
31
.7
00
24
.8
40
8.
48
90
2.
35
4
0.
01
85
  C
ol
la
ge
n 
ty
pe
 6
T
17
1.
60
13
0.
49
30
9.
76
2.
32
4
0.
02
01
  C
yt
oc
hr
om
e 
P4
50
T
11
9.
80
94
.6
03
13
1.
81
2.
19
5
0.
02
81
  D
ou
bl
e-
st
ra
nd
ed
 D
N
A
T
11
1.
00
75
.6
63
21
9.
56
2.
38
5
0.
01
70
  H
SC
T
45
.1
00
36
.0
30
19
.9
78
2.
02
9
0.
04
24
  H
SP
T
57
.5
00
44
.6
17
26
.0
77
2.
52
3
0.
01
16
  H
SP
T
29
9.
60
25
7.
26
20
28
.2
0.
94
0
0.
34
72
  H
SP
T
55
.9
00
42
.8
00
37
.9
17
2.
12
7
0.
03
33
  H
SP
T
27
5.
00
22
4.
32
82
4.
64
1.
76
5
0.
07
76
  H
SP
-9
0 
be
ta
T
21
8.
50
15
5.
02
16
52
.7
1.
56
1
0.
11
84
  H
is
to
ne
T
70
.4
00
56
.3
23
47
.4
64
2.
04
3
0.
04
10
  H
is
to
ne
 H
1
T
66
.0
00
51
.6
50
40
.7
17
2.
24
9
0.
02
45
  H
is
to
ne
 H
2A
T
10
8.
40
92
.8
40
15
1.
22
1.
26
5
0.
20
57
  H
is
to
ne
 H
2B
T
70
.9
00
84
.0
43
97
5.
67
-0
.4
21
0.
67
39
  H
is
to
ne
 H
3
T
89
.2
00
71
.7
77
90
.5
49
1.
83
1
0.
06
71
  H
is
to
ne
 H
4
T
48
.4
00
39
.9
20
16
.0
80
2.
36
4
0.
01
80
  I
ns
ul
in
T
55
.4
00
45
.6
10
25
.0
70
1.
95
5
0.
05
05
  J
O
-1
T
33
.0
00
26
.1
83
7.
82
20
2.
43
7
0.
01
47
  M
ito
ch
on
dr
ia
l
T
57
.2
00
43
.8
83
33
.6
33
2.
29
6
0.
02
16
  M
ye
lo
pe
ro
xi
da
se
T
57
.9
00
46
.2
50
24
.3
65
2.
36
0
0.
01
82
  P
C
N
A
T
75
.1
00
52
.8
77
87
.8
25
2.
37
1
0.
01
77
  P
M
-1
T
39
.0
00
29
.5
40
13
.0
90
2.
61
5
0.
00
89
J Mol Med (Berl). Author manuscript; available in PMC 2011 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Marballi et al. Page 14
A
lle
le
S
E(
S)
V
ar
(S
)
Z
P
  P
ro
te
in
as
e 
3
T
89
.9
00
69
.3
07
66
.1
56
2.
53
2
0.
01
13
  R
N
P
T
52
.2
00
40
.4
97
20
.9
60
2.
55
6
0.
01
05
  R
N
P-
A
T
22
4.
70
17
0.
57
87
5.
63
1.
82
9
0.
06
73
  R
N
P-
C
T
89
.7
48
75
.8
63
51
.8
94
1.
92
7
0.
05
39
  R
ib
os
om
al
 P
T
42
.6
00
32
.9
47
14
.7
26
2.
51
6
0.
01
18
  S
cl
er
od
er
m
a 
70
T
13
5.
00
19
7.
73
53
13
.8
-0
.8
61
0.
38
94
  S
m
ith
T
49
.5
00
37
.9
60
19
.8
66
2.
58
9
0.
00
96
  S
SA
T
44
.9
00
31
.2
80
67
.1
24
1.
66
2
0.
09
64
  S
SB
T
48
.3
00
37
.6
10
17
.5
01
2.
55
5
0.
01
06
  T
hy
ro
gl
ob
ul
in
T
88
.8
00
56
.9
60
43
9.
72
1.
51
8
0.
12
89
  T
hy
ro
id
 m
ic
ro
so
m
al
T
15
5.
90
11
4.
21
33
0.
98
2.
29
1
0.
02
19
  T
3
T
38
.9
00
30
.2
70
12
.4
38
2.
44
7
0.
01
44
  T
4
T
15
.2
70
12
.3
38
2.
04
1
2.
05
2
0.
40
17
C
yt
ok
in
e
  I
L1
2p
70
T
29
.1
89
23
.9
35
4.
77
0
2.
40
6
0.
01
61
  T
N
F
T
29
.8
39
24
.4
98
5.
47
2
2.
28
3
0.
02
24
  I
L1
0
T
29
.0
09
23
.1
96
6.
26
7
2.
32
2
0.
02
02
  I
L6
T
36
.4
99
30
.6
15
7.
81
1
2.
10
5
0.
03
52
  I
L1
b
T
40
.3
07
33
.6
91
9.
82
4
2.
11
1
0.
03
47
  I
L8
T
74
.4
44
63
.7
79
42
.1
62
1.
64
2
0.
10
05
P 
va
lu
es
 fo
r m
ar
ke
rs
 sh
ow
in
g 
hi
gh
er
 th
an
 e
xp
ec
te
d 
le
ve
ls
 o
f a
nt
ig
en
 a
ss
oc
ia
te
d 
w
ith
 th
e 
N
RG
1 
T 
al
le
le
 in
 1
4 
in
fo
rm
at
iv
e 
fa
m
ili
es
 a
re
 sh
ow
n 
in
 b
ol
d.
 C
yt
ok
in
e 
le
ve
ls
 w
er
e 
m
ea
su
re
d 
in
 p
la
sm
a 
us
in
g 
a
va
lid
at
ed
 c
yt
om
et
ric
 b
ea
d 
ar
ra
y 
sy
st
em
 (B
D
 B
io
sc
ie
nc
es
). 
A
ut
oa
nt
ib
od
y 
le
ve
ls
 w
er
e 
m
ea
su
re
d 
in
 p
la
sm
a 
us
in
g 
a 
va
lid
at
ed
 m
ul
tip
le
x 
im
m
un
oa
ss
ay
 d
ev
el
op
ed
 b
y 
R
ul
es
-B
as
ed
 M
ed
ic
in
e
(w
w
w
.ru
le
sb
as
ed
m
ed
ic
in
e.
co
m
)
S 
te
st
 st
at
is
tic
, E
(S
) e
xp
ec
te
d 
va
lu
e 
of
 th
e 
te
st
 st
at
is
tic
 u
nd
er
 a
 n
ul
l h
yp
ot
he
si
s o
f n
o 
as
so
ci
at
io
n
J Mol Med (Berl). Author manuscript; available in PMC 2011 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Marballi et al. Page 15
Ta
bl
e 
2
C
om
pa
ra
tiv
e 
m
R
N
A
 p
ro
fil
es
 in
 N
R
G
1 
V
al
/V
al
 a
nd
 V
al
/L
eu
 c
el
l l
in
es
G
en
e
A
ve
ra
ge
 ΔC
t m
ut
an
ts
A
ve
ra
ge
 ΔC
t c
on
tr
ol
s
2−
ΔC
t  m
ut
an
ts
2−
ΔC
t  c
on
tr
ol
s
Fo
ld
 d
iff
er
en
ce
 m
ut
an
ts
/c
on
tr
ol
s
t t
es
t P
 v
al
ue
IL
-4
16
.4
3
14
.7
9
1.
1E
–0
5
3.
5E
–0
5
↓ 3
.1
0
0.
03
40
IL
-6
8.
61
13
.0
5
2.
6E
9.
6E
↑ 2
7.
08
0.
04
04
IF
N
A2
11
.9
1
9.
60
2.
6E
1.
3E
↓ 5
.0
0
0.
05
05
BM
P8
B
11
.2
9
12
.9
4
4.
0E
1.
3E
↑ 3
.1
4
0.
04
59
D
at
a 
w
er
e 
ge
ne
ra
te
d 
us
in
g 
a 
co
m
m
on
 c
yt
ok
in
e 
ge
ne
 a
rr
ay
 (P
A
H
S 
02
1,
 S
A
B
io
sc
ie
nc
es
). 
Fo
ld
 u
p 
or
 d
ow
n 
ex
pr
es
si
on
 in
 m
ut
an
ts
 c
om
pa
re
d 
w
ith
 c
on
tro
ls
 is
 d
en
ot
ed
 b
y 
ar
ro
w
s. 
G
en
es
 sh
ow
n 
he
re
 a
re
 th
os
e
w
hi
ch
 sh
ow
ed
 si
gn
ifi
ca
nt
 e
vi
de
nc
e 
of
 d
iff
er
en
tia
l m
R
N
A
 e
xp
re
ss
io
n 
in
 m
ut
an
ts
 (V
al
/L
eu
, N
=5
) c
om
pa
re
d 
w
ith
 c
on
tro
ls
 (V
al
/V
al
, N
=6
): 
in
te
rle
uk
in
-4
 (I
L-
4)
, i
nt
er
le
uk
in
-6
 (I
L-
6)
, i
nt
er
fe
ro
n-
A
2 
(I
FN
A2
),
bo
ne
 m
or
ph
og
en
et
ic
 p
ro
te
in
 8
b 
(B
M
P8
). 
A
vg
 Δ
C
t=
(C
t(G
O
I)
–A
ve
 C
t (
H
K
G
en
e)
). 
C
t=
cy
cl
e 
th
re
sh
ol
d,
 m
in
im
um
 n
um
be
r o
f P
C
R
 c
yc
le
s n
ee
de
d 
to
 d
et
ec
t e
xp
re
ss
io
n.
 H
ig
h 
C
t=
lo
w
 e
xp
re
ss
io
n;
 lo
w
 C
t=
hi
gh
ex
pr
es
si
on
J Mol Med (Berl). Author manuscript; available in PMC 2011 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Marballi et al. Page 16
Ta
bl
e 
3
m
R
N
A
 e
xp
re
ss
io
n 
le
ve
ls
 o
f I
L6
 a
nd
 IL
4 
in
 N
R
G
1 
V
al
/V
al
 a
nd
 V
al
/L
eu
 c
el
l l
in
es
G
en
e
A
ve
ra
ge
 ΔC
t c
on
tr
ol
s
A
ve
ra
ge
 ΔC
t m
ut
an
ts
2−
ΔC
t  c
on
tr
ol
s
2−
ΔC
t  m
ut
an
ts
Fo
ld
 d
iff
er
en
ce
 m
ut
an
ts
/c
on
tr
ol
s
t t
es
t P
 v
al
ue
IL
-4
15
.9
02
40
18
.0
43
51
1.
62
E−
05
3.
70
E−
06
↓ 4
.3
9
0.
01
50
IL
-6
13
.8
28
99
   
 8
.6
81
12
8
6.
87
E−
05
2.
43
E−
03
↑ 3
5.
46
0.
00
11
Fo
ld
 u
p 
or
 d
ow
n 
ex
pr
es
si
on
 in
 m
ut
an
ts
 (V
al
/L
eu
, N
=5
) c
om
pa
re
d 
w
ith
 c
on
tro
ls
 (V
al
/V
al
, N
=6
) i
s d
en
ot
ed
 b
y 
ar
ro
w
s. 
A
vg
 Δ
C
t=
(C
t(G
O
I)
–A
ve
 C
 t 
(H
K
G
))
. C
t=
m
in
im
um
 n
um
be
r o
f P
C
R
 c
yc
le
s n
ee
de
d 
to
de
te
ct
 e
xp
re
ss
io
n.
 H
ig
h 
C
t=
lo
w
 e
xp
re
ss
io
n;
 lo
w
 C
t=
hi
gh
 e
xp
re
ss
io
n
J Mol Med (Berl). Author manuscript; available in PMC 2011 November 1.
